Literature DB >> 1503802

Retinoids and cancer prevention.

D L Hill1, C J Grubbs.   

Abstract

As indicated above, in some cases the effects of retinoids appear to be species-specific. Although retinyl acetate and 4-HPR are ineffective in preventing mammary cancer induced by DMBA or occurring spontaneously in mice, these retinoids prevent carcinogen-induced mammary cancer in rats. In contrast, retinoids have modest chemopreventive activity for bladder cancer in various strains of both mice and rats and may have some therapeutic and preventive effects in human bladder. Retinyl palmitate is reported to reduce the incidence of esophageal lesions in hamsters; however, retinyl acetate may increase the incidence of esophageal tumors in rats. Although 13-cis-RA reduces the incidence of spontaneous thymic lymphomas in AKR mice and C57Bl/10W mice exposed to X rays and has some therapeutic effect on myelodysplastic syndromes in humans, 4-HPR may enhance leukemic progression in patients with this syndrome. For treatment of this syndrome, selection of the proper retinoid appears to be important. Topically applied retinyl palmitate reduces the incidence of cervical cancer in hamsters, and topically applied RA has a therapeutic effect on cervical dysplasia in humans. Retinamides have a modest chemopreventive effect against pancreatic cancer in rats dosed with azaserine; these compounds are reported both to increase and to decrease the incidence of pancreatic cancer in hamsters. Retinoids may, or may not, be carcinogen-specific in different species. Some are effective in preventing mammary cancer in rats, regardless of which carcinogen is used. Applied to mouse skin, retinoids are active with either DMBA or BP as the carcinogen and 12-tetradecanoyl phorbol-13-acetate (TPA) as the promoter. Nevertheless, retinoids are not effective in preventing skin papillomas and carcinomas caused by UV light. There is no comparable system for humans, although retinoids demonstrate activity against basal cell carcinomas, squamous cell carcinomas, and actinic keratoses on the skin of humans. Fewer bladder tumors develop in rats dosed with HO-BBN when they are put on diets containing certain retinoids, but those dosed with FANFT are not affected. Similarly, retinyl acetate is reported to be active against liver tumors induced by 3'-MeDAB but not against those induced by aflatoxin B1. In contrast, forestomach carcinomas induced in hamsters by either DMBA or BP are prevented by retinyl palmitate. The route of administration of retinoids may also be important.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1503802     DOI: 10.1146/annurev.nu.12.070192.001113

Source DB:  PubMed          Journal:  Annu Rev Nutr        ISSN: 0199-9885            Impact factor:   11.848


  8 in total

1.  Virtual coupling of pyran protons in the 1H NMR spectra of C- and N-glucuronides [correction]: dependence on substitution and solvent.

Authors:  M J Panigot; M J Robarge; R W Curley
Journal:  AAPS PharmSci       Date:  2001

Review 2.  Clinical pharmacokinetics of tretinoin.

Authors:  M B Regazzi; I Iacona; C Gervasutti; M Lazzarino; S Toma
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

3.  The receptor-DNA complex determines the retinoid response: a mechanism for the diversification of the ligand signal.

Authors:  N La Vista-Picard; P D Hobbs; M Pfahl; M I Dawson; M Pfahl
Journal:  Mol Cell Biol       Date:  1996-08       Impact factor: 4.272

4.  Altered localization of retinoid X receptor alpha coincides with loss of retinoid responsiveness in human breast cancer MDA-MB-231 cells.

Authors:  T Tanaka; B L Dancheck; L C Trifiletti; R E Birnkrant; B J Taylor; S H Garfield; U Thorgeirsson; L M De Luca
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

5.  Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off.

Authors:  M B Regazzi; D Russo; I Iacona; S Sacchi; G Visani; M Lazzarino; G Avvisati; P G Pelicci; G Dastoli; C Grandi; S Spreafico; R Grattoni; P Galieni; S Rupoli; A M Maiolo; E Guerra; A M Liberati
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 6.  Perspectives in cancer chemoprevention.

Authors:  G D Stoner; M A Morse; G J Kelloff
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

7.  Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease.

Authors:  Jun Wang; Weina Bi; Wei Zhao; Merina Varghese; Rick J Koch; Ruth H Walker; Roshantha A Chandraratna; Martin E Sanders; Amanda Janesick; Bruce Blumberg; Libby Ward; Lap Ho; Giulio M Pasinetti
Journal:  Oncotarget       Date:  2016-02-16

8.  The Effect of Metformin Treatment on CRBP-I Level and Cancer Development in the Liver of HBx Transgenic Mice.

Authors:  Jo-Heon Kim; Md Morshedul Alam; Doek Bae Park; Moonjae Cho; Seung-Hong Lee; You-Jin Jeon; Dae-Yeul Yu; Tae Du Kim; Ha Young Kim; Chung Gu Cho; Dae Ho Lee
Journal:  Korean J Physiol Pharmacol       Date:  2013-10-17       Impact factor: 2.016

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.